Last reviewed · How we verify
Cohort 1: Lubiprostone Capsule, Fasted
Lubiprostone activates ClC-2 chloride channels in the intestinal epithelium to increase intestinal fluid secretion and promote bowel motility.
Lubiprostone activates ClC-2 chloride channels in the intestinal epithelium to increase intestinal fluid secretion and promote bowel motility. Used for Chronic idiopathic constipation, Opioid-induced constipation, Irritable bowel syndrome with constipation.
At a glance
| Generic name | Cohort 1: Lubiprostone Capsule, Fasted |
|---|---|
| Also known as | AMITIZA®, Treatment A |
| Sponsor | Sucampo Pharma Americas, LLC |
| Drug class | Chloride channel activator |
| Target | ClC-2 chloride channel |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Lubiprostone is a selective activator of ClC-2 chloride channels located on the apical membrane of gastrointestinal epithelial cells. By opening these channels, it increases chloride and fluid secretion into the intestinal lumen, which increases stool frequency and alleviates constipation. This mechanism enhances intestinal motility and hydration without systemic absorption or effects on other organ systems.
Approved indications
- Chronic idiopathic constipation
- Opioid-induced constipation
- Irritable bowel syndrome with constipation
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
- Headache
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: